According to a company press release, Kuros Biosciences has been awarded the Spine Technology Award 2020 for its technology that delivers targeted and controlled bone formation. The award was presented at a gala on Thursday by the widely-read industry journal “Orthopedics This Week”. Joost de Bruijn, Chief Executive Officer of Kuros, commented in the press release: “I would like to thank Orthopedics This Week for their consideration of Kuros, which rewards the hard work and dedication of our employees and support of our investors”.
The International Life Sciences Award from the Internet platform Global Health and Pharma (GHP) was also presented to Kuros this November. This makes Kuros the first company to be recognized by GHP for solutions in connection with spinal surgery.
These prizes are the icing on the cake following “a year of strong progress” for Kuros, the press release states. Sales figures for the lead product MagnetOs are rapidly on the rise, while the company has also launched a Phase II study with Fibrin-PTH. This is the first investigational trial of a drug biologic bone graft for spinal fusion.
These successes have been underpinned by a capital increase that was conducted owing to “strong demand”. The process raised gross proceeds in the amount of 18.6 million Swiss francs from both existing investors and new institutional investors. “Kuros has had an exciting year”, de Bruijn concludes.
Kuros Biosciences, which specializes in developing products in the area of wound healing and tissue regeneration, is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH). The company is headquartered at Bio-Technopark Schlieren-Zurich.